Document Detail


Fenofibrate for the treatment of type IV and V hyperlipoproteinemias: a double-blind, placebo-controlled multicenter US study.
MedLine Citation:
PMID:  2655907     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The results of a randomized, double-blind, placebo-controlled multicenter trial of fenofibrate in the treatment of type IV/V hyperlipoproteinemia are reported. Ten study centers in the United States recruited 147 adults with a history of type IV or V hyperlipoproteinemia. After a six- to 12-week dietary stabilization period and a four-week placebo period, patients whose 12-hour fasting total plasma triglyceride levels ranged from 350 to 1,500 mg/dl were continued in the study; 55 patients with levels of 350 to 499 mg/dl were placed in group A and 92 with levels of 500 to 1,500 mg/dl in group B. Patients in each group were randomly assigned to receive 100 mg of fenofibrate or placebo three times daily for eight weeks. In both groups A and B fenofibrate-treated patients showed statistically significant reductions in levels of total cholesterol, very-low-density lipoprotein cholesterol, total triglycerides, and very-low-density lipoprotein triglycerides, and significant increases in high-density lipoprotein cholesterol; patients in group B also showed a significant increase in low-density lipoprotein cholesterol levels. Sixteen of the 75 fenofibrate-treated patients and 11 of the 72 placebo patients reported adverse events that were potentially drug related; most of these were gastrointestinal and a few reported musculoskeletal and skin reactions. It is concluded that fenofibrate is an effective and safe agent in the treatment of type IV/V hyperlipoproteinemia.
Authors:
A C Goldberg; G Schonfeld; E B Feldman; H N Ginsberg; D B Hunninghake; W Insull; R H Knopp; P O Kwiterovich; M J Mellies; J Pickering
Related Documents :
12019107 - Efficacy of zidovudine compared to stavudine, both in combination with lamivudine and i...
6355937 - Endocrine and metabolic effects of low-dose estrogen-progestin treatment in climacteric...
7500507 - Effects of lowering elevated ldl cholesterol on the cardiovascular risk of lipoprotein(a).
1280577 - Safety profile of acarbose, an alpha-glucosidase inhibitor.
18162017 - Ethyl-eicosapentaenoic acid in first-episode psychosis: a randomized, placebo-controlle...
24316697 - Prospective double-blind clinical trial evaluating the effectiveness of bromelain in th...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Clinical therapeutics     Volume:  11     ISSN:  0149-2918     ISO Abbreviation:  Clin Ther     Publication Date:  1989  
Date Detail:
Created Date:  1989-06-27     Completed Date:  1989-06-27     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  7706726     Medline TA:  Clin Ther     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  69-83     Citation Subset:  IM    
Affiliation:
Washington University, St. Louis, Missouri.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Aged
Cholesterol / blood
Clinical Trials as Topic
Double-Blind Method
Female
Humans
Hyperlipoproteinemia Type IV / drug therapy*
Hyperlipoproteinemia Type V / drug therapy*
Male
Middle Aged
Procetofen / adverse effects,  therapeutic use*
Propionates / therapeutic use*
Random Allocation
Time Factors
Triglycerides / blood
United States
Chemical
Reg. No./Substance:
0/Propionates; 0/Triglycerides; 49562-28-9/Procetofen; 57-88-5/Cholesterol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Relief of epigastric pain in nonulcer dyspepsia: controlled trial of the promotility drug cisapride.
Next Document:  The role of nicardipine during anesthesia and surgery.